Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 32 (2012), Issue 1, Pages 43-50
http://dx.doi.org/10.3233/DMA-2012-0859

Prevalence of MDR1 C3435T and CYP2B6 G516T Polymorphisms among HIV-1 Infected South African Patients

Tracy Madimabi Masebe,1 Pascal Obong Bessong,1 Julius Nwobegahay,1 Roland Ndip Ndip,2,3 and Debra Meyer4

1AIDS Virus Research Laboratory, Department of Microbiology, University of Venda, Thohoyandou, South Africa
2Department of Biochemistry and Microbiology, University of Fort Hare, Alice, South Africa
3Department of Life Sciences, University of Buea, Buea, Cameroon
4Department of Biochemistry, University of Pretoria, Pretoria, South Africa

Received 19 January 2012; Accepted 19 January 2012

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Data on genetic polymorphisms associated with response to anti-HIV drugs has accumulated over the years. Information on how polymorphisms influence drug metabolism and transport to target sites is important in guiding dosage or selection of appropriate alternative therapies. This study determined the frequency of MDR1 C3435T and CYP2B6 G516T polymorphisms associated with the transport and metabolism of efavirenz and nevirapine, in a population of South African HIV infected patients. In addition, association of polymorphisms with immunologic and virologic factors was investigated. A 207bp of MDR1 exon 26 and a 161bp of CYP2B6 exon 4 were obtained from patients by polymerase chain reaction. Analysis of population-based sequences of MDR1 revealed a frequency of 89% and 11% of C and T alleles respectively (n=197; X2 = 0.974; p=0.324). Restriction fragment length polymorphism (RFLP) analysis of the CYP2B6 gene revealed a prevalence of 9.5% of GG, 78.4% of GT and 12.1% of TT genotype (n= 199; X2 = 65.204; p=0.00). There was no significant difference between immune recovery and decline in viral load (n=53), with genotype after repeated calculations of analysis of variance (ANOVA).